Navigation Links
NewCardio Announces Financial Results for Its 2010 Third Quarter
Date:11/15/2010

gnated; 2,920 and -0- shares issued and outstanding as of September 30, 2010 and December 31, 2009, respectively

3

-Preferred stock Series D, $0.001 par value; 1,000 shares designated; no shares issued and outstanding as of September 30, 2010 and December 31, 2009

-

-Common stock, $0.001 par value, 500,000,000 and 99,000,000 shares authorized as of September 30, 2010 and December 31, 2009, respectively; 29,871,857 and 24,290,279 shares issued and outstanding as of September 30, 2010 and December 31, 2009, respectively

29,872

24,290Stock subscription

500,000

-Additional paid in capital

37,371,015

29,432,680Deficit accumulated during development stage

(39,215,289)

(30,930,360)  Total stockholders' deficit

(1,314,387)

(1,473,374)$
3,852,512

$
2,301,318NEWCARDIO, INC

(a development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFrom September 7, 2004Three months ended
September 30,

Nine months ended
September 30,

(date of inception) through2010

2009

2010

2009

September 30, 2010Revenue

$99,210

$ -

$169,328

$
-

$
9,328Cost of sales

37,937

-

84,468

-

84,468Gross (loss) profit

61,273

-

84,860

-

84,860Operating expenses:Selling, general and administrative

1,185,170

1,538,141

4,732,292

4,821,003

16,296,612Depreciation

20,446

17,941

59,191

41,249

138,232Research and development

748,401

796,168

2,674,089

2,338,589

9,007,193 Total operating expenses

1,954,017

2,352,250

7,465,572

7,200,841

25,442,037Net loss from operations

(1,892,744)

(2,352,250)

(7,380,712)

(7,200,841)

(25,357,177)Other income (expense)
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NewCardio Announces Positive Results From Third Clinical Validation Study
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Leadership to Present Two Abstracts at ISCE Conference
4. NewCardio Announces Master Services Agreement With Dedicated Phase I
5. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
6. NewCardio Announces Financial Results for the First Half of 2010 and Commercialization Progress
7. NewCardio CEO Increases Equity Position
8. NewCardio to Present Results of QTinno Performance on Cardiac Safety Research Consortium Blinded Testing Dataset
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... VIEJO , Kalifornien, 20. Mai 2013 ... bekannt, dass das Unternehmen die CE-Kennzeichnung für ... zur Embolisation von Aneurysmen erhalten hat. Das ... Europa bereits mit der kontrollierten Einführung dieser ... bietet die SL-Produktfamilie auch ein verbessertes Handling, ...
(Date:5/20/2013)... LONDON , BERLIN ... 2013 Arthroscopy Devices Market ... Preference for Minimally Invasive Procedures to Drive Future Growth" ... trends for the six arthroscopy device market segments: arthroscopes, ... arthroscopy radio frequency systems, and arthroscopy visualization systems. The ...
(Date:5/20/2013)... 2013  Neuralstem, Inc. (NYSE MKT: CUR) today reported ... principal investigator, presented updated Phase I data from its ... the treatment of amyotrophic lateral sclerosis (ALS or ... diabetes special medical symposium in Bucharest, Romania ... Therapeutic Advances in Stem Cell Therapy," Dr. Feldman outlined ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- A child whose ... relatively higher risk for developing a respiratory infection before ... Researchers looked at data involving nearly 1,300 pairs of ... began study participation while in their first trimester of ... About 6 percent of the mothers lived within 100 ...
(Date:5/20/2013)... In celebration of National Women’s Health Week and ... The Feinstein Institute for Medical Research and ... in Science and Medicine (AWSM) , hosted its second ... business and community leaders from the region attended the ... science. , “Women face unique barriers to success ...
(Date:5/20/2013)... emergency departments play a growing role in the U.S. ... hospital admissions and serving increasingly as an advanced diagnostic ... RAND Corporation study. , While often targeted as the ... remain an important safety net for Americans who cannot ... slowing the growth of health care costs, according to ...
(Date:5/20/2013)... ANN ARBOR, Mich. As high schoolers prepare for ... a "study drug" -- a prescription stimulant or amphetamine ... University of Michigan poll shows only one in 100 ... teen has used a study drug., Study drugs refer ... attention deficit hyperactivity disorder (ADHD); commonly prescribed medicines in ...
(Date:5/20/2013)... 2013) Wolters Kluwer Health is ... Wilkins (LWW) published journals won 13 ASHPE awards ... member articles and publications for editorial, design, print ... honor to be recognized year after year for ... the industry with quality, depth, and impact," said ...
Breaking Medicine News(10 mins):Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Hospital emergency departments gaining in importance, study finds 2Health News:Hospital emergency departments gaining in importance, study finds 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2
... Quad Will Become the Highest-Selling Antiretroviral in the ... from Decision ResourcesWALTHAM, Mass., May 19 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... six percent annual growth in the HIV drug ...
... ( www.apieron.com ) significantly strengthened its senior ... Vice President, Sales & Marketing, and Bryan Miller as ... Bubrick has more than 20 years of operational and ... in diabetes management. Prior to joining Apieron, Mr. Bubrick ...
... May 19 New Life Agency filed suit against ... contract.This lawsuit grew out of a previous contractual relationship ... in December 2005. Once New Life Agency assumed direct ... for New Life,s Surrogate Maternity and Cycle Medical Plan(R), ...
... Has 6 Front Range LocationsDENVER, May 19 Clinic ... Solutions, announced today the firm has secured an agreement ... to all Front Range MedExpress Urgent Care locations. ... nationwide reach."This is a key new contract for us," ...
... INTERESTS ARE NOT ALIGNED WITH STOCKHOLDERSADVOCAT BOARD NEEDS TO ... May 19 Bristol Investment Fund, Ltd. ("Bristol") announced ... stockholders of Advocat, Inc. (the "Company") (Nasdaq: ... qualified and independent director nominees, Paul Kessler and Richard ...
... be Issued from Among Intradigm,s Large Collection of ... Intradigm Corporation, a leading developer of targeted, ... issuance of United States patent 7,534,878, titled "Composition ... Cancer and Other Neovascularization Diseases." The issued ...
Cached Medicine News:Health News:Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013 2Health News:Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013 3Health News:Apieron Strengthens Senior Leadership With Commercial, Financial Appointments 2Health News:New Life Agency, Inc. Continues to Trial Against Beitler Services, Inc. in Pursuit of Payments for Surrogate Maternity Claims 2Health News:New Life Agency, Inc. Continues to Trial Against Beitler Services, Inc. in Pursuit of Payments for Surrogate Maternity Claims 3Health News:Clinic Service Announces Agreement to Provide Billing Service to MedExpress 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 2Health News:Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 3
... Eppendorf Mastercycler Family offers fast temperature control, ... optimal flexibility. Personal cards enable safe program ... transfer of individual protocols between different Mastercyclers. ... PCR and come with a two-year warranty. ...
... The latest addition to ... thermal cyclers is the personal-sized ... ideal instrument for both basic ... It represents the culmination of ...
... well thermocycler with unique High ... for fastest available heating and ... with High Pressure Lid for ... Includes motorized lid for ...
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
Medicine Products: